FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB

FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB Share Price

DE000SH7M2V2

Delayed Deutsche Boerse AG 17:04:05 03/06/2024 BST
19.23 ^EUR	-18.48%

1 month	+65.20%
3 months	+221.39%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	03:14pm	BU
Bristol Myers: presents advances in lung cancer	01:58pm	CF
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	01:09pm	BU
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE

More news

Quotes 5-day view

Date	Price	Change
03/06/24	19.23	-18.48%
31/05/24	23.59	-10.37%
30/05/24	26.32	+0.53%
29/05/24	26.18	+1.51%
28/05/24	25.79	+21.36%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 05:04 pm

More quotes

Static data

Product type	Produits Exotiques
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SH7M2V
ISIN	DE000SH7M2V2
Date issued	18/03/2022
Strike	69.69 $
Maturity	Unlimited
Parity	1 : 1
Emission price	10.07 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	28.2 €
Lowest since issue	0.89 €
Spread	0.22 €
Spread %	1.13%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus